Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (23)
Thomas Wilke, Burkhard Weisser, Hans-Georg Predel, Roland Schmieder, Sven Wassmann, Anton Gillessen, Jörg Blettenberg, Ulf Maywald, Olaf Randerath, Sabrina Mueller & Michael Böhm. (2022) Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study. Integrated Blood Pressure Control 15, pages 11-21.
Read now
Read now
Xin Wang, Hua Chen, Essien E, Jun Wu, Omar Serna, Rutugandha Paranjpe & Susan Abughosh. (2021) Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 829-836.
Read now
Read now
Young-Mi Ah, Jaekyu Shin & Ju-Yeun Lee. (2019) The association of angiotensin receptor blocker-based combination therapy with persistence and adherence in newly treated, uncomplicated hypertensive patients. Patient Preference and Adherence 13, pages 241-248.
Read now
Read now
Paulina Lopatowska, Elzbieta Mlodawska, Anna Tomaszuk-Kazberuk, Maciej Banach & Jolanta Malyszko. (2018) Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Review of Clinical Pharmacology 11:2, pages 165-170.
Read now
Read now
C. Vlachopoulos, V. Grammatikou, M. Kallistratos & A. Karagiannis. (2016) Effectiveness of perindopril/amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study. Current Medical Research and Opinion 32:9, pages 1605-1610.
Read now
Read now
Jing Hao, Rosa Rodriguez-Monguio & Enrique Seoane-Vazquez. (2016) Fixed-dose combination and single active ingredient drugs: a comparative cost analysis. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 127-134.
Read now
Read now
G. Machnicki, S.H. Ong, W. Chen, Z.J. Wei & K.H. Kahler. (2015) Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. Current Medical Research and Opinion 31:12, pages 2287-2296.
Read now
Read now
Susanne Roas, Felix Bernhart, Michael Schwarz, Walter Kaiser & Georg Noll. (2014) Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland. International Journal of General Medicine 7, pages 549-556.
Read now
Read now
Lin Xie, Feride Frech-Tamas, Elizabeth Marrett & Onur Baser. (2014) A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Current Medical Research and Opinion 30:12, pages 2415-2422.
Read now
Read now
Danny H Sugimoto, Steven G Chrysant, Michael Melino, James Lee, Victor Fernandez & Reinilde Heyrman. (2013) The TRINITY Study: distribution of systolic blood pressure reductions. Integrated Blood Pressure Control 6, pages 89-99.
Read now
Read now
Addison A Taylor & Shawn Ragbir. (2012) Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension. Patient Preference and Adherence 6, pages 555-563.
Read now
Read now
L. Breitscheidel, B. Ehlken, K. Kostev, M. S. A. Oberdiek, A. Sandberg & R. E. Schmieder. (2012) Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. Journal of Medical Economics 15:1, pages 155-165.
Read now
Read now
Steven G. Chrysant. (2011) Single-Pill Triple-Combination Therapy: An Alternative to Multiple-Drug Treatment of Hypertension. Postgraduate Medicine 123:6, pages 21-31.
Read now
Read now
Atsushi Sakima, Katsuhiko Ohshiro, Seigo Nakada, Masanobu Yamazato, Kentaro Kohagura, Minori Nakamoto, Takeshi Tana & Yusuke Ohya. (2011) Switching Therapy from Variable-Dose Multiple Pill to Fixed-Dose Single-Pill Combinations of Angiotensin II Receptor Blockers and Thiazides for Hypertension. Clinical and Experimental Hypertension 33:5, pages 309-315.
Read now
Read now
Weiyi Yang, Kristijan H. Kahler, Thomas Fellers, John Orloff, Joanne Chang, Arielle G. Bensimon, Eric Q. Wu, Chun-Po Steve Fan & Andrew P. Yu. (2011) Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. Journal of Medical Economics 14:3, pages 267-278.
Read now
Read now
Rainer Düsing. (2010) Optimizing blood pressure control through the use of fixed combinations. Vascular Health and Risk Management 6, pages 321-325.
Read now
Read now
Rainer Düsing. (2010) Valsartan/amlodipine single pill combination for the treatment of hypertension. Expert Review of Clinical Pharmacology 3:6, pages 739-746.
Read now
Read now
Joanne Chang, Weiyi Yang, Thomas Fellers, Kristijan H. Kahler, John Orloff, Jipan Xie, Magda Tsaneva, Andrew P. Yu & Eric Q. Wu. (2010) Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. Current Medical Research and Opinion 26:9, pages 2203-2212.
Read now
Read now
Weiyi Yang, Joanne Chang, Kristijan H. Kahler, Thomas Fellers, John Orloff, Eric Q. Wu & Arielle G. Bensimon. (2010) Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Current Medical Research and Opinion 26:9, pages 2065-2076.
Read now
Read now
Ji-Guang Wang. (2009) A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vascular Health and Risk Management 5, pages 593-605.
Read now
Read now
David T Nash & Michael S McNamara. (2009) Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility. Integrated Blood Pressure Control 2, pages 39-54.
Read now
Read now
Yves Lacourcière, Luc Poirier & Rita Samuel. (2009) Valsartan plus hydrochlorothiazide for first-line therapy in hypertension. Expert Review of Cardiovascular Therapy 7:12, pages 1491-1501.
Read now
Read now
Maria Czarina Acelajado, David A Calhoun & Suzanne Oparil. (2009) Reduction of blood pressure in patients with treatment-resistant hypertension. Expert Opinion on Pharmacotherapy 10:18, pages 2959-2971.
Read now
Read now
Articles from other publishers (46)
Qiran Wei, Jiting Zhou, Hongchao Li, Luying Wang, Yao Wu, Aixia Ma & Xin Guan. (2023) Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis. Frontiers in Pharmacology 14.
Crossref
Crossref
Paweł Bryniarski, Katarzyna Nazimek & Janusz Marcinkiewicz. (2021) Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response. International Journal of Molecular Sciences 23:1, pages 74.
Crossref
Crossref
S. R. Gilyarevskij, N. G. Bendeliani, M. V. Golshmid, I. M. Kuz’mina & I. G. Andreeva. (2021) THE APPLICATION OF COMBINED PREPARATIONS WITH CONSTANT DOSES OF ANTIHYPERTENSIVE DRUGS AS THE INITIAL TACTICS OF TREATMENT AT HIGH BLOOD PRESSURE LEVEL: PROVEN FACTS AND EXPERT’S OPINION. Eurasian heart journal:2, pages 92-102.
Crossref
Crossref
Zhen-Yu Zhang, Yu-Ling Yu, Kei Asayama, Tine W. Hansen, Gladys E. Maestre & Jan A. Staessen. (2021) Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension 77:3, pages 788-798.
Crossref
Crossref
Apichard Sukonthasarn, Yook‐Chin Chia, Ji‐Guang Wang, Jennifer Nailes, Peera Buranakitjaroen, Huynh Van Minh, Narsingh Verma, Satoshi Hoshide, Jinho Shin, Yuda Turana, Jam Chin Tay, Boon Wee Teo, Saulat Siddique, Jorge Sison, Yu‐Qing Zhang, Tzung‐Dau Wang, Chen‐Huan Chen & Kazuomi Kario. (2020) The feasibility of polypill for cardiovascular disease prevention in Asian Population. The Journal of Clinical Hypertension 23:3, pages 545-555.
Crossref
Crossref
T. E. Morozova & E. O. Samokhina. (2020) Fixed-dose combinations in the treatment of hypertension to increase adherence. Russian Journal of Cardiology 25:11, pages 4184.
Crossref
Crossref
Erika Campana, Vitória Cunha, Sigita Glaveckaite, Ivan Gruev, Guillaume Lamirault, Elke Lehmann, Stefano Masi, Liliane Mfeukeu Kuate, Larysa Mishshenko, Deborah I.D. Ona, Min Zaw Oo, Oana G.F. Tautu, Anna Vachulova, Ana-Maria Vintila, Jacek Wolf, Nadezhda Zvartau, Krzysztof Narkiewicz & Stephane Laurent. (2020) The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. Journal of Hypertension 38:12, pages 2369-2377.
Crossref
Crossref
Xin Wang, Hua Chen, E. J. Essien, Jun Wu, Omar Serna, Rutugandha Paranjpe & Susan Abughosh. (2020) Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). American Journal of Cardiovascular Drugs 20:6, pages 591-602.
Crossref
Crossref
Burkhard Weisser, Hans-Georg Predel, Anton Gillessen, Claudia Hacke, Johannes vor dem Esche, Gerd Rippin, Andrea Noetel & Olaf Randerath. (2020) Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. High Blood Pressure & Cardiovascular Prevention 27:2, pages 157-164.
Crossref
Crossref
Ana Baumgartner, Katarina Drame, Stijn Geutjens & Marja Airaksinen. (2020) Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics 12:2, pages 190.
Crossref
Crossref
Xin WangHua ChenEkere EssienJun Wu, Omar SernaRutugandha ParanjpeSusan Abughosh. (2019) Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. Journal of Managed Care & Specialty Pharmacy 25:6, pages 678-686.
Crossref
Crossref
Kostas Tsioufis, Stella Douma, Manolis S. Kallistratos & Athanasios J. Manolis. (2019) Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension. Clinical Drug Investigation 39:4, pages 385-393.
Crossref
Crossref
Stelina Alkagiet & Konstantinos Tziomalos. (2018) Suboptimal Adherence to Antihypertensive Treatment: Causes and Management. The Open Hypertension Journal 10:1, pages 41-45.
Crossref
Crossref
Li‐Ping Du, Zhong‐Wei Cheng, Yu‐Xuan Zhang, Ying Li & Dan Mei. (2018) The impact of fixed‐dose combination versus free‐equivalent combination therapies on adherence for hypertension: a meta‐analysis. The Journal of Clinical Hypertension 20:5, pages 902-907.
Crossref
Crossref
Marcus J. Drake, Sally Bowditch, Emilio Arbe, Zalmai Hakimi, Florent Guelfucci, Ikbel Amri & Jameel Nazir. (2017) A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urology 17:1.
Crossref
Crossref
Andrea L. Schaffer, Nicholas A. Buckley & Sallie-Anne Pearson. (2017) Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. Pharmacoepidemiology and Drug Safety 26:12, pages 1465-1473.
Crossref
Crossref
R Düsing, B Waeber, M Destro, C Santos Maia & P Brunel. (2017) Triple-combination therapy in the treatment of hypertension: a review of the evidence. Journal of Human Hypertension 31:8, pages 501-510.
Crossref
Crossref
Louise E. Bartlett, Nicole Pratt & Elizabeth E. Roughead. (2017) Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?. British Journal of Clinical Pharmacology 83:1, pages 202-210.
Crossref
Crossref
Andrea L. Schaffer, Sallie-Anne Pearson & Nicholas A. Buckley. (2016) How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014). British Journal of Clinical Pharmacology 82:4, pages 1134-1145.
Crossref
Crossref
O. V. Machilskaya. (2016) The factors determining adherence to treatment in arterial hypertension patients (literature review). Kardiologiya i serdechno-sosudistaya khirurgiya 9:3, pages 55.
Crossref
Crossref
C.-I. Hsu, F.-Y. Hsiao, F.-L. L. Wu & L.-J. Shen. (2015) Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker/thiazide diuretics among newly diagnosed hypertensive patients: a population-based cohort study. International Journal of Clinical Practice 69:7, pages 729-737.
Crossref
Crossref
M. Chris Runken, Bridgett Goodwin, Manan Shah, Michael Eaddy, Anna D’Souza, Brian Bowers & Christopher F. Bell. (2014) Migraine-Related Healthcare Resource Use and Costs for Subjects Prescribed Fixed-Dose Combination Sumatriptan/Naproxen Sodium vs. Single-Entity Oral Triptans in a Managed Care Population in the USA. Applied Health Economics and Health Policy 13:1, pages 109-120.
Crossref
Crossref
Vanessa Christe, Gérard Waeber, Peter Vollenweider & Pedro Marques-vidal. (2014) Antihypertensive drug treatment changes in the general population: the colaus study. BMC Pharmacology and Toxicology 15:1.
Crossref
Crossref
Gregg Lanier, Kedar Sankholkar & Wilbert S. Aronow. (2014) Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin–Angiotensin–Aldosterone System Antagonists. American Journal of Therapeutics 21:5, pages 419-435.
Crossref
Crossref
M.H.D. Wasem Alsabbagh, Mark Lemstra, Dean Eurich, Lisa M. Lix, Thomas W. Wilson, Erin Watson & David F. Blackburn. (2014) Socioeconomic Status and Nonadherence to Antihypertensive Drugs: A Systematic Review and Meta-Analysis. Value in Health 17:2, pages 288-296.
Crossref
Crossref
Manabu Akazawa & Katsushi Fukuoka. (2013) Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Services Research 13:1.
Crossref
Crossref
Benjamin J. Epstein, Niren K. Shah & Nancy L. Borja-Hart. (2013) Management of hypertension with fixed-dose triple-combination treatments. Therapeutic Advances in Cardiovascular Disease 7:5, pages 246-259.
Crossref
Crossref
Joel M. Neutel & David H. G. Smith. (2013) Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action. Cardiovascular Therapeutics 31:5, pages 251-258.
Crossref
Crossref
Andrew J. Lewin, Joseph L. IzzoJrJr, Michael Melino, James Lee, Victor Fernandez & Reinilde Heyrman. (2013) Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age. Drugs & Aging 30:7, pages 549-560.
Crossref
Crossref
D. S. H. Bell. (2012) Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy. Diabetes, Obesity and Metabolism 15:4, pages 291-300.
Crossref
Crossref
Carlos M. Ferrario, Sumeet Panjabi, Paul Buzinec & Jason P. Swindle. (2013) Clinical and economic outcomes associated with amlodipine/renin–angiotensin system blocker combinations. Therapeutic Advances in Cardiovascular Disease 7:1, pages 27-39.
Crossref
Crossref
Sumeet Panjabi, Michael Lacey, Timothy Bancroft & Felix Cao. (2013) Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. Journal of the American Society of Hypertension 7:1, pages 46-60.
Crossref
Crossref
Dean J Kereiakes, Steven G Chrysant, Joseph L IzzoJrJr, Thomas LittlejohnIIIIII, Michael Melino, James Lee, Victor Fernandez & Reinilde Heyrman. (2012) Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology 11:1.
Crossref
Crossref
Dean J. Kereiakes, Steven G. Chrysant, Joseph L. IzzoJrJr, Thomas LittlejohnIIIIII, Suzanne Oparil, Michael Melino, James Lee, Victor Fernandez & Reinilde Heyrman. (2012) Long‐Term Efficacy and Safety of Triple‐Combination Therapy With Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide for Hypertension. The Journal of Clinical Hypertension 14:3, pages 149-157.
Crossref
Crossref
Lawrence Blonde & Zinnia T. San Juan. (2012) Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Advances in Therapy 29:1, pages 1-13.
Crossref
Crossref
Beth Sherrill, Michael Halpern, Shahnaz Khan, Jie Zhang & Sumeet Panjabi. (2011) Single-Pill vs Free-Equivalent Combination Therapies for Hypertension: A Meta-Analysis of Health Care Costs and Adherence. The Journal of Clinical Hypertension 13:12, pages 898-909.
Crossref
Crossref
Howard S Weintraub & Amy Rudolph. (2011) Combination Therapy for Managing Difficult-to-Treat Patients With Stage 2 Hypertension: Focus on Valsartan-Based Combinations. American Journal of Therapeutics 18:6, pages e227-e243.
Crossref
Crossref
M. Belén Ferro-Rey, Alex Roca-Cusachs, Antoni Sicras-Mainar, Carlos Álvarez-Martín & Marina de Salas-Cansado. (2011) Las combinaciones fijas en hipertensión: análisis de impacto presupuestario para el Sistema Nacional de Salud Español de la comercialización de la combinación fija de olmesartan/amlodipino. Atención Primaria 43:7, pages 345-355.
Crossref
Crossref
Suzanne Oparil, Michael Melino, James Lee, Victor Fernandez & Reinilde Heyrman. (2010) Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clinical Therapeutics 32:7, pages 1252-1269.
Crossref
Crossref
Martin C S Wong, Johnny Y Jiang & Sian M Griffiths. (2010) Adherence to combination therapy among ethnic Chinese patients: a cohort study. Hypertension Research 33:5, pages 416-421.
Crossref
Crossref
Brigitte Dréno, Diane Thiboutot, Harald Gollnick, Andrew Y. Finlay, Alison Layton, James J. Leyden, Eric Leutenegger & Montserrat Perez. (2010) Large-scale worldwide observational study of adherence with acne therapy. International Journal of Dermatology 49:4, pages 448-456.
Crossref
Crossref
Hein AW van Onzenoort, Willem J Verberk, Abraham A Kroon, Alfons GH Kessels, Patricia J Nelemans, Paul-Hugo M van der Kuy, Cees Neef & Peter W de Leeuw. (2010) Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension. Journal of Hypertension 28:3, pages 622-627.
Crossref
Crossref
Michael H. Kim, Jay Lin, Mohamed Hussein, Charles Kreilick & David Battleman. (2009) Cost of atrial fibrillation in United States managed care organizations. Advances in Therapy 26:9, pages 847-857.
Crossref
Crossref
Michael H. Kim, Jay Lin & Charles Kreilick. (2009) National assessment of medicare prescription plan coverage gaps among patients with atrial fibrillation in the US. Advances in Therapy 26:8, pages 784-794.
Crossref
Crossref
Stefano Carugo, Giuseppe Rossetti, Luca Merlino & Giuseppe Mancia. (2009) Prescription Data Related to the Use of Calcium Channel Blockers, ACE Inhibitors and Angiotensin II Type 1 Receptor Antagonists (Angiotensin Receptor Blockers) in Combination Identify Savings Opportunities. High Blood Pressure & Cardiovascular Prevention 16:1, pages 21-26.
Crossref
Crossref
M. Burnier, R. E. Brown, S. H. Ong, A. Keskinaslan & Z. M. Khan. (2009) Issues in blood pressure control and the potential role of single-pill combination therapies. International Journal of Clinical Practice 63:5, pages 790-798.
Crossref
Crossref